Cardiac tumors medical therapy
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors medical therapy On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors medical therapy |
|
Risk calculators and risk factors for Cardiac tumors medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Dj
Overview
Most of the Cardiac tumors are treated with surgical management. Malignant primary cardiac tumors have a predisposition for rapid metastasis spread.
- Systemic neoadjuvant therapy should be aggressively explored in hemodynamically stable patients with localized disease because it permits: (a) quicker removal by shrinking the tumor size and (b) a decrease in the likelihood of systemic recurrence
Medical Treatment of Cardiac Tumors
| Tumor | Treatment |
|---|---|
| Cardiac Lymphoma | Rituximab is an anti-CD20 monoclonal antibody that typically produces remission in a wide range of B-cell non-Hodgkin lymphomas.
MOA: Activation of antibody-dependent, cell-mediated cytotoxicity, complement-mediated lysis, phagocytosis of antibody-coupled tumor cells, and activation of cell death appear to constitute its mode of action.[1] |
| Sarcoma | Doxorubicin and Ifosfamide alternative regimen Gemcitabine/Docetaxel |
| Angiosarcoma | Paclitaxel |
References
- ↑ Nakagawa Y, Ikeda U, Hirose M, Ubukata S, Katsuki TA, Kaminishi Y; et al. (2004). "Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab)". Circ J. 68 (2): 172–3. doi:10.1253/circj.68.172. PMID 14745155.